文献速递脑血管病

抗磷脂抗体在缺血性卒中中的患病率及临床相关性:系统综述与荟萃分析

Prevalence and Clinical Relevance of Antiphospholipid Antibodies in Ischemic Stroke: A Systematic Review and Meta-Analysis.
PubMed 文献 · Stroke · 2026-08-28

该系统综述与荟萃分析纳入52项研究,评估抗磷脂抗体(aPL)在缺血性卒中患者中的患病率及其与首发和复发卒中的关联。结果显示,缺血性卒中患者中任何aPL血清阳性的合并患病率为19.1%(95%CI 15.4%-23.0%),aPL阳性与首发缺血性卒中风险升高相关(OR 2.93,95%CI 2.31-3.73),但与复发卒中风险无显著关联(OR 1.20,95%CI 0.87-1.67)。

要点

  • 近1/5缺血性卒中患者存在任何aPL血清阳性。
  • aPL阳性与首发缺血性卒中风险升高相关,狼疮抗凝物关联最强。
  • aPL阳性与复发缺血性卒中风险无显著关联。

核心结论

  • 任何aPL血清阳性见于近1/5的缺血性卒中患者,并与首发缺血性卒中风险升高相关。
  • aPL血清阳性与复发缺血性卒中风险无显著关联。

研究设计与样本

  • 系统检索PubMed和Embase截至2025年5月13日,纳入病例对照、队列或横断面研究。
  • 共纳入52项研究(40项病例对照,12项队列),采用随机效应模型合并患病率和OR。

主要发现

  • 缺血性卒中患者(51项研究,9438例)任何aPL血清阳性的合并患病率为19.1%(95%CI 15.4%-23.0%;I2=95.8%)。
  • 狼疮抗凝物关联最强(OR 6.69,95%CI 2.94-15.2;I2=92.6%),IgG型抗心磷脂抗体OR为2.56(95%CI 1.96-3.35;I2=92.5%)。
  • aPL血清阳性与复发缺血性卒中风险无显著差异(9项研究,2873例;OR 1.20,95%CI 0.87-1.67;I2=11.4%)。

关键数值与推荐

  • aPL血清阳性定义为IgG/IgM型抗心磷脂抗体、IgG/IgM型抗β2糖蛋白I抗体或狼疮抗凝物任一阳性。

临床怎么用

  • 对缺血性卒中患者可考虑检测aPL以评估首发卒中风险,尤其狼疮抗凝物。
  • aPL阳性与复发卒中关联不显著,复发风险评估需结合其他因素。

局限性

  • 纳入研究间异质性较高(如患病率I2=95.8%)。
  • 原始摘要未报告其他局限性信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Antiphospholipid antibodies (aPL) are associated with an increased risk of thrombosis. However, individual studies have reported conflicting findings regarding the prevalence of aPL in patients with ischemic stroke and their association with first or recurrent events. METHODS: Systematic searches of PubMed and Embase through May 13, 2025 were conducted to identify case-control, cohort, or cross-sectional studies investigating 3 questions related to aPL seropositivity (defined as positivity for either immunoglobulin G/immunoglobulin M anticardiolipin antibody, immunoglobulin G/immunoglobulin M anti-β2 glycoprotein I antibody, or a lupus anticoagulant): (1) the prevalence of aPL seropositivity among individuals with ischemic stroke; (2) the association between aPL seropositivity and the risk of first ischemic stroke; and (3) the association between aPL seropositivity and the risk of recurrent ischemic stroke. Random-effects models with inverse weighting were used to calculate pooled prevalences and odds ratios (OR) with 95% CIs. Risk of bias was assessed using the ROBINS-I tool. RESULTS: A total of 52 studies were included (40 case-control, 12 cohort). The pooled prevalence of seropositivity for any aPL among patients with ischemic stroke (51 studies, 9438 patients) was 19.1% (95% CI, 15.4%-23.0%; I2=95.8%). aPL seropositivity was associated with higher odds of first ischemic stroke (43 studies, 19 097 patients; OR, 2.93 [95% CI, 2.31-3.73]; I2=68.7%). The strongest associations were for lupus anticoagulant (OR, 6.69 [95% CI, 2.94-15.2]; I2=92.6%) and immunoglobulin G anticardiolipin antibody (OR, 2.56 [95% CI, 1.96-3.35]; I2=92.5%). The odds of recurrent ischemic stroke among patients with versus without any aPL seropositivity were not significantly different (OR, 1.20 [95% CI, 0.87-1.67]; 9 studies, 2873 patients, I2=11.4%). CONCLUSIONS: Seropositivity for any aPL was present in nearly 1-in-5 patients with ischemic stroke and was associated with increased odds of ischemic stroke at presentation.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Watson NW, Bukhari S, Rashedi S, et al. Prevalence and Clinical Relevance of Antiphospholipid Antibodies in Ischemic Stroke: A Systematic Review and Meta-Analysis. Stroke. 2026. PMID: 42663055. doi:10.1161/STROKEAHA.126.055247

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。